If there is going to be a reorganization holding mid-management accountable for product approvals may be prudent at this point in the game. Upper management has all been replaced recently. It is the mid-management that has been around for ages. If there are delays in product approvals this year it is time to look closely at mid-management. Did they make their timelines? If not it is time to do some serious thinking about restaffing mid-management.
Other than the name change to Development & Research there has been no real effort to shift more of the companies resources to development. So many people sitting on their -%$# and working on patents and publications but not contributing to the product development. No shift of resources and a poor team effort from the people currently in the research group for Development support leads to what we have. -- No product approvals from the FDA--